LinkedIn post<\/a>, Mittal said the rising popularity of GLP-1 drugs reflects a desire for results without sustained effort, even as demand for Ozempic surges across urban India.<\/p>\nHe noted that Ozempic is already selling in India at around Rs 8,800 per month and estimates the market could reach nearly Rs 1,000 crore annually. He said interest in such drugs is likely to intensify further from March 2026, when patents on several GLP-1 treatments begin to expire, potentially opening the space to wider competition from Indian pharmaceutical companies.<\/p>\n
\u201cDemand is real. Curiosity is massive. The real plot twist lands in March \u201926, when GLP-1 patents begin to expire. That\u2019s when every pharma company will discover its inner weight-loss baba and the industry could 5\u00d7 in a few years,\u201d he wrote.<\/p>\n
\u201cIf Ozempic becomes for fat loss what Eno is for acidity, half of urban India may be on a monthly injection plan, just to look better on Instagram.\u201d<\/p>\n
At the same time, Mittal acknowledged the medical value of GLP-1 drugs, calling them \u201cgenuinely life-changing\u201d for patients with obesity, diabetes, and serious metabolic conditions.<\/p>\n
However, he cautioned that for the average person, reliance on injections purely for appearance risks normalising unhealthy shortcuts.<\/p>\n
\u201cShortcuts are seductive. Science is powerful. But fitness ka jugaad nahi hota, boss,\u201d he wrote, stressing that long-term health still depends on disciplined lifestyle choices such as balanced nutrition, regular exercise, adequate sleep, and daily movement.<\/p>\n
Netizens reaction<\/p>\n
Mittal\u2019s post sparked an animated debate on LinkedIn, with many users shared their perspective on the growing Ozempic trend and the broader conversation around fitness versus convenience.<\/p>\n
\u201cShortcuts can help, but they can\u2019t replace the basics. Discipline, nutrition, exercise, and sleep will always be the foundation,\u201d a user wrote.<\/p>\n
\u201cThis post offers a thought-provoking take on the intersection of science and lifestyle in the quest for fitness. With the potential flood of generics post-2026, it seems crucial to balance medical advances with sustainable health habits. How do you see the generics market impacting the healthcare message around personal responsibility and lifestyle changes?,\u201d another wrote.<\/p>\n
\u201cFitness has never been about a single tool, it has always been about daily behaviour stacking. Shortcuts feel attractive, but lifestyle still compounds the longest. Discipline may not trend on Instagram, but it protects everything else,\u201d a third said.<\/p>\n","protected":false},"excerpt":{"rendered":"People Group founder and Shark Tank India judge Anupam Mittal has cautioned against the growing use of diabetes…\n","protected":false},"author":2,"featured_media":240792,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[274],"tags":[45870,18,135,19,17,462,45874],"class_list":{"0":"post-240791","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-anupam-mittal","9":"tag-eire","10":"tag-health","11":"tag-ie","12":"tag-ireland","13":"tag-medication","14":"tag-shark-tank-india"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115745607259955665","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/240791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=240791"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/240791\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/240792"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=240791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=240791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=240791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}